Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab.
Giannis S MountziosVassiliki KotoulaGeorgia-Angeliki KolliouKyriaki PapadopoulouGeorgios LazaridisChristos ChristodoulouGeorge PentheroudakisMaria SkondraAngelos KoutrasHelena LinardouEvangelia RazisPavlos PapakostasSofia ChrisafiGerasimos AravantinosIrene NicolaouAnna GoussiaKonstantine KalogerasDimitrios PectasidesGeorge FountzilasPublished in: ESMO open (2019)
Aberrant activation of the cyclin D1-mediated pathway appears to reduce the risk of progression in HER2-negative tumours, but not in HER2-positive ones.